Urinary protein biomarker panel predicts esophageal squamous carcinoma from control cases and other tumors

Ji, Linlin; Wang, Jianping; Yang, Bo; Zhu, Jianping; Wang, Yini; Jiao, Jiaqi; Zhu, Kai; Zhang, Min; Zhai, Liqiang; Gong, Tongqing; Sun, Changqing; Qin, Jun; Wang, Guangshun

doi:10.1007/s10388-022-00932-7

Cited by 3 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urinary protein may serve as a biomarker for ESCC. Li et al [ 25 ] conducted a proteomics analysis on 499 human urine samples (321 healthy individuals, 83 with ESCC, 17 with bladder cancer, 12 with breast cancer, 16 with colorectal cancer, 33 with lung cancer, and with 17 thyroid cancer). The results suggested that urinary biomarkers ANXA1, S100A8, and TMEM256 can classify ESCC, and a panel of proteins consisting of ANXA1, S100A8, SOD3, and TMEM256 is diagnostic for stage I ESCC.…”

Section: Non-invasive Biomarkers: Blood Plasma Saliva and Urine Bioma...mentioning

confidence: 99%

Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Rai

Abdo

Agrawal

2023

IJMS

View full text Add to dashboard Cite

Esophageal cancer (EC) is the deadliest cancer worldwide, with a 92% annual mortality rate per incidence. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of ECs, with EAC having one of the worst prognoses in oncology. Limited screening techniques and a lack of molecular analysis of diseased tissues have led to late-stage presentation and very low survival durations. The five-year survival rate of EC is less than 20%. Thus, early diagnosis of EC may prolong survival and improve clinical outcomes. Cellular and molecular biomarkers are used for diagnosis. At present, esophageal biopsy during upper endoscopy and histopathological analysis is the standard screening modality for both ESCC and EAC. However, this is an invasive method that fails to yield a molecular profile of the diseased compartment. To decrease the invasiveness of the procedures for diagnosis, researchers are proposing non-invasive biomarkers for early diagnosis and point-of-care screening options. Liquid biopsy involves the collection of body fluids (blood, urine, and saliva) non-invasively or with minimal invasiveness. In this review, we have critically discussed various biomarkers and specimen retrieval techniques for ESCC and EAC.

show abstract

Section: Non-invasive Biomarkers: Blood Plasma Saliva and Urine Bioma...mentioning

confidence: 99%

Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Rai

Abdo

Agrawal

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Because of their non-invasiveness, ease of use, costeffectiveness, short-term repeatability, and capacity to identify circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosome-based biomarkers for both EAC and ESCC, and liquid biopsy and blood biomarkers are gaining a lot of attention [154]. According to a proteomic study, the urine biomarkers ANXA1, S100A8, and TMEM256 may be used to categorize ESCC, and a panel of proteins made up of these proteins can be used to diagnose stage I ESCC [155]. Potential biomarkers include the expression of chemokines and chemokine receptors in serum, which are additional components implicated in the pathogenesis of EAC and ESCC.…”

Section: Biomarkersmentioning

confidence: 99%

Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies

Panda

Verma

Lakkakula

2023

Onco

View full text Add to dashboard Cite

Esophageal cancer is a formidable challenge in the realm of cancer treatment. Conventional methods such as surgery, chemotherapy, and immunotherapy have demonstrated limited success rates in managing this disease. In response, targeted drug therapies have emerged as a promising strategy to improve outcomes for patients. These therapies aim to disrupt specific pathways involved in the growth and development of esophageal cancer cells. This review explores various drugs used to target specific pathways, including cetuximab and monoclonal antibodies (gefitinib) that target the epidermal growth factor receptor (EGFR), trastuzumab that targets human epidermal growth factor receptor 2 (HER-2), drugs targeting the vascular endothelial growth factor receptor (VEGFR), mTOR inhibitors, and cMET inhibitors. Additionally, the article discusses the impact of drug resistance on the effectiveness of these therapies, highlighting factors such as cancer stem cells, cancer-associated fibroblasts, immune-inflammatory cells, cytokines, hypoxia, and growth factors. While drug targeting approaches do not provide a complete cure for esophageal cancer due to drug resistance and associated side effects, they offer potential for improving patient survival rates.

show abstract

Prognostic and clinicopathological value of Ki-67 in patients with oesophageal squamous cell carcinoma: a systematic review and meta-analysis

Wang,

Dai,

Chen

2024

BMJ Open

View full text Add to dashboard Cite

ObjectivesThe relationship between Ki-67 expression and the prognosis of patients with oesophageal squamous cell carcinoma (ESCC) has been extensively studied. However, their findings were inconsistent. Consequently, the present meta-analysis was performed to identify the precise value of Ki-67 in predicting the prognosis of ESCC.DesignThe current meta-analysis was carried out in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.Data sourcesElectronic databases of PubMed, Embase, Web of Science and Cochrane Library were systematically searched until 26 September 2023.Statistical methodsPooled HRs and corresponding 95% CIs were calculated to estimate the role of Ki-67 in predicting overall survival (OS) and disease-free survival (DFS) in ESCC. Between-study heterogeneity was evaluated using Cochrane’s Q test and I2statistics. Specifically, significant heterogeneities were identified based on p<0.10 on the Q statistic test or I2>50% so the random-effects model should be used; otherwise, the fixed-effects model should be used. The relationship between Ki-67 and clinicopathological characteristics of ESCC was evaluated by combining ORs with their corresponding 95% CIs.Results11 articles with 1124 patients were included in the present meta-analysis. Based on our analysis, increased Ki-67 expression was markedly associated with poor OS (HR 1.62, 95% CI 1.15 to 2.28, p=0.006) and DFS (HR 1.72, 95% CI 1.22 to 2.43, p=0.002) in ESCC. Moreover, subgroup analysis revealed that Ki-67 upregulation significantly predicted OS and DFS when a Ki-67 threshold of >30% was used. Nonetheless, Ki-67 was not significantly associated with sex, T stage, N stage, TNM stage, tumour differentiation or tumour location.ConclusionsIn the present meta-analysis, high Ki-67 expression significantly predicted OS and DFS in patients with ESCC, especially when Ki-67>30% was used as the threshold. These results suggest that Ki-67 could serve as an effective and reliable prognostic indicator for ESCC.

show abstract

Urinary protein biomarker panel predicts esophageal squamous carcinoma from control cases and other tumors

Cited by 3 publications

References 42 publications

Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies

Prognostic and clinicopathological value of Ki-67 in patients with oesophageal squamous cell carcinoma: a systematic review and meta-analysis

Contact Info

Product

Resources

About